Interdisciplinary model‐informed drug development for extending duration of elagolix treatment in patients with uterine fibroids

AIM: Elagolix, a gonadotropin‐releasing hormone receptor antagonist, was recently approved for heavy menstrual bleeding associated with uterine fibroids (UF, Oriahnn) at a dose of 300 mg twice daily (BID) in combination with add‐back therapy (oestradiol 1 mg/norethindrone acetate 0.5 mg [E2/NETA] on...

Descripción completa

Detalles Bibliográficos
Autores principales: Beck, Denise, Winzenborg, Insa, Gao, Wei, Mostafa, Nael M., Chiuve, Stephanie E., Owens, Charlotte, Shebley, Mohamad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796281/
https://www.ncbi.nlm.nih.gov/pubmed/35695781
http://dx.doi.org/10.1111/bcp.15440

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796281/
https://www.ncbi.nlm.nih.gov/pubmed/35695781
http://dx.doi.org/10.1111/bcp.15440

Ejemplares similares